Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on PTCT stock, giving a Hold rating yesterday.Stay Ahead of the ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

Good morning, Boston. Here are the five things you need to know in local business news to start your post-holiday Friday.

PTC Industries, a high-growth defence stock up 1,200% in three years, closed a Rs 700 crore QIP with investments from Motilal Oswal, HSBC, and Societe Generale. The QIP increased the company's equity ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...